Health ❯ Healthcare ❯ Drug Development

Regulatory Affairs

FDA Approval Animal Testing Alternatives Clinical Trials FDA Designations FDA Approval Process Drug Discontinuation EMA Approval FDA Processes FDA Submissions FDA Applications Biologics License Application

Athira Pharma Secures Exclusive Lasofoxifene Rights, Raises $90 Million to Advance Phase 3 Breast Cancer Program

Fresh funding is slated to carry the late-stage study toward a mid-2027 readout pending an expected closing next week.

DBV Peanut Allergy Patch Succeeds in Pivotal Phase 3, Setting Up 2026 FDA Filing

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

Mixed Phase 3 Outcomes Cloud Future of Regeneron and Sanofi’s COPD Candidate Itepekimab